Chemokine beta-1 fusion proteins

• US 20030143191A1
• Filed: 05/24/2002
• Published: 07/31/2003
• Est. Priority Date: 05/25/2001
• Status: Abandoned Application

• Current Assignee: Human Genome Sciences Incorporated (GSK plc)
• Original Assignee: Human Genome Sciences Incorporated (GSK plc)
• Inventors: Bell, Adam, Ruben, Steven M.
• Application Number:
  US10/153,604
• Publication Number:
  US 20030143191A1
• Time in Patent Office: Days
• US Class Current: 424/85.1
• CPC Class Codes: A61P 31/18 for HIV
• CPC Class Codes: C07K 14/523 Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
• CPC Class Codes: C07K 2319/00 Fusion polypeptide

Abstract

The present invention relates to novel chemokine polypeptides and encoding nucleic acids. More specifically, therapeutic compositions and methods are provided using isolated nucleic acid molecules encoding a human chemokine beta-1 (Ckβ-1 or Ckb1) polypeptide (previously termed monocyte-colony inhibitory factor (M-CIF), MIP1-γ, and Hemofiltrate CC chemokine-1 (HCC-1)), and Ckb1 polypeptides themselves, as are vectors, host cells and recombinant methods for producing the same. Also provided are methods of treating, preventing, ameliorating diseases using such compounds.

Claims

1. A Ckb1 protein comprising a deletion in amino acid residues selected from:

(a) the amino terminus, (b) the carboxy terminus, and (c) the amino terminus and carboxy terminus of the polypeptide shown in FIG. 1 (SEQ ID NO;

2).

2. The Ckb1 protein of claim 1, selected from the group consisting of:

(a) a polypeptide comprising residues 5 to n, wherein n is any one of residues 56-74 of SEQ ID NO;

2;

(b) a polypeptide comprising residues 6 to n, wherein n is any one of residues 56-74 of SEQ ID NO;

2;

(c) a polypeptide comprising residues 7 to n, wherein n is any one of residues 56-74 of SEQ ID NO;

2;

(d) a polypeptide comprising residues 8 to n, wherein n is any one of residues 56-74 of SEQ ID NO;

2;

(e) a polypeptide comprising residues 9 to n, wherein n is any one of residues 56-74 of SEQ ID NO;

2;

3. The Ckb1 protein of claim 1, further comprising first a heterologous protein.

4. The Ckb1 protein of claim 3, wherein said first heterologous protein is human serum albumin (HSA).

5. The Ckb1 protein of claim 4, wherein said HSA comprises SEQ ID NO:

X.

6. The Ckb1 protein of claim 4, wherein said HSA is at the N-terminus of Ckb1.

7. The Ckb1 protein of claim 4, wherein said HSA is at the C-terminus of Ckb1.

8. The Ckb1 protein of claim 4, further comprising a second heterologous protein.

9. The Ckb1 protein of claim 8, wherein said second heterologous protein is at the N-terminus of Ckb1.

10. The Ckb1 protein of claim 8 or claim 9, wherein said second heterologous protein is 4 amino acids in length.

11. The Ckb1 protein of any one of claims 1 to 10, which is selective for CCR5.

12. A method of preventing infection in a cell in need thereof comprising contacting said cell with an effective amount of the Ckb1 protein of any one of claims 1 to 11.

13. The method of claim 12, wherein said infection is a viral infection.

14. The method of claim 13, wherein said viral infection is HIV infection.

15. A method of treating a disease in an individual comprising administering an effective amount of the Ckb1 protein of any one of claims 1 to 11.

16. The method of claim 15, wherein said disease is HIV infection.

17. The method of claim 15, wherein said disease is selected from the group consisting of:

immune disorders, hematopoietic disorders, autoimmune disorders, multiple sclerosis, Grave'"'"'s disease, arthritis, rheumatoid arthritis, transplant rejection, neurodegenerative disorders, Alzheimer'"'"'s disease, inflammatory disorders, asthma, allergic disorders, inflammatory bowel disease, osteoarthritis, colitits, inflammatory kidney diseases, glomerulonephritis, infectious diseases, tuburculosis, Hepatitis infections, herpes viral infections, viral infections, proliferative disorders, and atherosclerosis.